Moderate-to-severe envenoming requiring ViperaTAb antivenom therapy in the UK.
Lamb, Thomas Stewart, David Warrell, David A Lalloo, David G Jagpal, Pardeep Jones, Dacia Thanacoody, Ruben Gray, Laurence A Eddleston, Michael
Lamb, Thomas
Stewart, David
Warrell, David A
Lalloo, David G
Jagpal, Pardeep
Jones, Dacia
Thanacoody, Ruben
Gray, Laurence A
Eddleston, Michael
Citations
Altmetric:
Affiliation
Royal Infirmary of Edinburgh; University of Oxford; Liverpool School of Tropical Medicine; Sandwell and West Birmingham NHS Trust
Other Contributors
Publication date
2021-03-15
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Bites by the European adder (Vipera berus) in the UK are uncommon but potentially life threatening, and can be associated with marked limb swelling and disability. Following an interruption in Zagreb Imunološki zavod antivenom supply around 2012, the UK changed its national choice of antivenom for Vipera berus to ViperaTAb, an ovine Fab monospecific antivenom. In the absence of randomised controlled trials, we established an audit to review its use in clinical practice.
Citation
Lamb T, Stewart D, Warrell DA, Lalloo DG, Jagpal P, Jones D, Thanacoody R, Gray LA, Eddleston M. Moderate-to-severe Vipera berus envenoming requiring ViperaTAb antivenom therapy in the UK. Clin Toxicol (Phila). 2021 Nov;59(11):992-1001.
Type
Article